Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes

INTRODUCTION: Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin-producing β cells of the pancreas. One immunosuppressive agent that has recently shown promise in the treatment of new-onset T1D subjects aged 12–45 years is antithymocyte glo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilhelm-Benartzi, Charlotte S, Miller, Sarah E, Bruggraber, Sylvaine, Picton, Diane, Wilson, Mark, Gatley, Katrina, Chhabra, Anita, Marcovecchio, M Loredana, Hendriks, A Emile J, Morobé, Hilde, Chmura, Piotr Jaroslaw, Bond, Simon, Aschemeier-Fuchs, Bärbel, Knip, Mikael, Tree, Timothy, Overbergh, Lut, Pall, Jaivier, Arnaud, Olivier, Haller, Michael J, Nitsche, Almut, Schulte, Anke M, Mathieu, Chantal, Mander, Adrian, Dunger, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655536/
https://www.ncbi.nlm.nih.gov/pubmed/34876434
http://dx.doi.org/10.1136/bmjopen-2021-053669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655536/
https://www.ncbi.nlm.nih.gov/pubmed/34876434
http://dx.doi.org/10.1136/bmjopen-2021-053669

Ejemplares similares